These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26709799)

  • 1. Inflammasomes in non-alcoholic fatty liver disease.
    Xiao J; Tipoe GL
    Front Biosci (Landmark Ed); 2016 Jan; 21(4):683-95. PubMed ID: 26709799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
    Liu J; Wang T; He K; Xu M; Gong JP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NLRP3 inflammasome activation is required for fibrosis development in NAFLD.
    Wree A; McGeough MD; Peña CA; Schlattjan M; Li H; Inzaugarat ME; Messer K; Canbay A; Hoffman HM; Feldstein AE
    J Mol Med (Berl); 2014 Oct; 92(10):1069-82. PubMed ID: 24861026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
    Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
    J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis.
    Csak T; Pillai A; Ganz M; Lippai D; Petrasek J; Park JK; Kodys K; Dolganiuc A; Kurt-Jones EA; Szabo G
    Liver Int; 2014 Oct; 34(9):1402-13. PubMed ID: 24650018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High fat diet feeding results in gender specific steatohepatitis and inflammasome activation.
    Ganz M; Csak T; Szabo G
    World J Gastroenterol; 2014 Jul; 20(26):8525-34. PubMed ID: 25024607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
    He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
    Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Emerging Relevance of AIM2 in Liver Disease.
    Lozano-Ruiz B; González-Navajas JM
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH.
    Wan X; Xu C; Yu C; Li Y
    Can J Gastroenterol Hepatol; 2016; 2016():6489012. PubMed ID: 27446858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
    Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
    Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of Perilipin 5 Protects Against Hepatic Injury in Nonalcoholic Fatty Liver Disease via Missing Inflammasome Activation.
    Asimakopoulou A; Engel KM; Gassler N; Bracht T; Sitek B; Buhl EM; Kalampoka S; Pinoé-Schmidt M; van Helden J; Schiller J; Weiskirchen R
    Cells; 2020 May; 9(6):. PubMed ID: 32481590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis.
    Cannito S; Morello E; Bocca C; Foglia B; Benetti E; Novo E; Chiazza F; Rogazzo M; Fantozzi R; Povero D; Sutti S; Bugianesi E; Feldstein AE; Albano E; Collino M; Parola M
    PLoS One; 2017; 12(3):e0172575. PubMed ID: 28249038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inflammasome in liver injury and non-alcoholic fatty liver disease.
    Mehal WZ
    Dig Dis; 2014; 32(5):507-15. PubMed ID: 25034283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tim-4 Inhibits NLRP3 Inflammasome via the LKB1/AMPKα Pathway in Macrophages.
    Liu W; Bai F; Wang H; Liang Y; Du X; Liu C; Cai D; Peng J; Zhong G; Liang X; Ma C; Gao L
    J Immunol; 2019 Aug; 203(4):990-1000. PubMed ID: 31263038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Tilg H; Moschen AR; Szabo G
    Hepatology; 2016 Sep; 64(3):955-65. PubMed ID: 26773297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
    Pierantonelli I; Svegliati-Baroni G
    Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic SPARC Expression Is Associated with Inflammasome Activation during the Progression of Non-Alcoholic Fatty Liver Disease in Both Mice and Morbidly Obese Patients.
    Onorato AM; Lameroli Mauriz L; Bayo J; Fiore E; Cantero MJ; Bueloni B; García M; Lagües C; Martínez-Duartez P; Menaldi G; Paleari N; Atorrasagasti C; Mazzolini GD
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease.
    Lee HJ; Yeon JE; Ko EJ; Yoon EL; Suh SJ; Kang K; Kim HR; Kang SH; Yoo YJ; Je J; Lee BJ; Kim JH; Seo YS; Yim HJ; Byun KS
    World J Gastroenterol; 2015 Dec; 21(45):12787-99. PubMed ID: 26668503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.